Objective: To evaluate the single-dose pharmacokinetics (PK), pharmacodynamics (PD), and safety of sitagliptin in pediatric patients with type 2 diabetes mellitus (T2DM).
| INTRODUCTION
The incidence and prevalence of type 2 diabetes mellitus (T2DM) in juvenile populations have been increasing for decades, 1,2 resulting in ever larger numbers of individuals who are exposed to hyperglycemia for longer periods of time, leading to earlier onset of complications. 3 Despite this, approved treatments for pediatric populations with T2DM remain limited.
The pathogenic defects associated with T2DM are similar in adults and youths, 3, 4 and therapies that are effective in one population are likely to be effective in the other. Sitagliptin, a dipeptidyl peptidase-4 (DPP- 4) inhibitor, is an antihyperglycemic agent approved for treatment of T2DM in adults. In numerous studies, sitagliptin was well tolerated 5 and efficacious as monotherapy [6] [7] [8] [9] and in combination with metformin, [10] [11] [12] [13] [14] [15] [16] [17] [18] among other antihyperglycemic agents. Thus, it could be a valuable additional agent for treatment of T2DM in a pediatric population.
By inhibiting DPP-4, sitagliptin blocks the degradation of glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide, enhancing glucose-stimulated insulin release and thereby decreasing both fasting glucose and post-meal glucose excursion with minimal risk of hypoglycemia. 19 In adults, sitagliptin has been found to be generally safe and well tolerated up to the maximum doses tested, 800 mg/ day in healthy subjects 20 and 200 mg/day in patients with T2DM. 21 The registered dose of sitagliptin in adults is 100 mg once daily.
Given the similarity in the body weights of pediatric patients 10 to17
years of age and adult patients with T2DM, and the maturity of the physiological processes involved with the absorption, distribution, metabolism, and elimination in pediatric patients, it was anticipated that the pharmacokinetics of sitagliptin would be similar between both populations. If a similar pharmacokinetic (PK) and pharmacodynamic (PD) profile for pediatric patients compared with adults after single 100 mg drug dose were observed, it would suggest that the appropriate efficacious dose of sitagliptin for pediatric patients would be similar to adults.
In the study reported here, the safety, tolerability, plasma PK and PD profiles of single doses of 50, 100, and 200 mg sitagliptin in 10-to 17-year-olds with T2DM were assessed, and the PK results were compared with historical results obtained in adults with T2DM. The effects of these doses on parameters related to glucose metabolism in the 10-to 17-year-old population were also evaluated.
| METHODS

| Participants
Thirty-five male and female participants, 10 to 17 years old and with T2DM were enrolled in the study. T2DM was documented and confirmed in the medical record at least 3 months prior to randomization, based on laboratory determinations of fasting glucose (≥126 mg/dL Concomitant use of metformin was permitted during the study provided the participant had been receiving a stable dose for at least 12 weeks prior to the dose of study drug, but was withheld prior to study drug administration and for 24 hours post-dose.
Written, informed consent was provided by a parent or legal guardian. Where appropriate, participants also provided assent.
| Study Design
This was a multicenter, randomized, double-blind, placebo-controlled, single-dose study with 4 panels of 8 to 9 participants each, randomized according to a computer-generated allocation schedule to receive single oral doses of sitagliptin or placebo in a 3:1 ratio, respectively. 
| Study Objectives
The primary objectives of this study were to assess the safety and tolerability of single doses of sitagliptin, and to obtain preliminary plasma AUC 0−∞ following single-dose administration of sitagliptin in 10-to 17-year-olds with T2DM. Secondary objectives were to obtain preliminary plasma AUC 0-24hr , C max , T max , and apparent t 1/2 following singledose administration of sitagliptin and to assess the effects over time of single doses of sitagliptin on plasma DPP-4 activity. Exploratory objectives were to assess the effects of single doses of sitagliptin on post-OGTT and post-meal incremental glucose, insulin, C-peptide, and glucagon concentrations, as well as on active and total GLP-1 levels, and to assess the relationship between PK parameters (eg, AUC 0-24hr , C max , T max , and apparent t 1/2 ) and PD parameters (insulin, C-peptide, plasma DPP-4 activity, and active GLP-1 levels).
| Safety and tolerability parameters
The safety and tolerability of sitagliptin was monitored by clinical assessment of AEs and by repeated measurements of vital signs, physical examinations, 12-lead electrocardiograms (ECGs), capillary blood glucose measurements, and standard laboratory safety tests (hematology, chemistry, and urinalysis) for at least 7 days post-dose and a minimum of 10 days for the entire study (including pre-and post-study visits). Safety and tolerability were assessed by individual investigators at each dose level prior to progression to the next panel.
| Pharmacokinetics
For determination of plasma sitagliptin concentrations, 4 mL of blood was drawn at indicated time points through an indwelling intravenous catheter. For determination of urinary sitagliptin concentrations, spot urine samples were collected pre-dose and all urine was collected over the subsequent intervals of 0 to 6, 6 to 12, and 12 to 24 hours post-dose.
Plasma and urine samples collected during the study were analyzed for sitagliptin concentrations by Pharmanet Canada Inc.
(Québec, Canada) and Merck Research Laboratories (West Point, Pennsylvania), respectively, as previously described. 22, 23 Non-compartmental plasma PK parameters were calculated using These analyses included at least three terminal points. Apparent terminal t ½ was calculated as ln(2)/λz.
Urinary PK parameters were calculated from urine concentrations, urine volumes from individual collection intervals, and actual times for the urine collection intervals. Sitagliptin renal clearance (Cl R )
was determined as the quotient of amount of sitagliptin excreted unchanged in urine over the dosing interval (0−τ) and AUC 0−τ .
| Pharmacodynamics
DPP-4 enzyme activity was assessed in plasma as previously described. 24 Active glucagon-like peptide-1 plasma concentrations were measured using a protocol and reagents from MesoScale Discovery (Rockville, Maryland). Total GLP-1 was measured using an radioimmunoassay protocol and reagents from Millipore (formerly Linco, St. Charles, Missouri). Plasma glucose, insulin, C-peptide, and glucagon were measured by PPD Global Central Labs, Highland Heights, KY.
| Statistical methods
| Pharmacokinetics
Appropriate transformations of the PK parameters were used (log transformation for AUC 0−∞ , C max and C 24hr ) and back-transformed summary statistics are reported. Dose proportionality for sitagliptin AUC 0−∞ was assessed using a power law model. The estimated slope and corresponding 90% confidence interval (CI) were summarized.
The adult sitagliptin AUC 0−∞ dose-adjusted to 100 mg (N = 7 adults with T2DM, 25 mg and 200 mg doses) 21 was used for comparison with that of the 10-to 17-year-old patients in the present study.
Since AUC 0−∞ is dose proportional over a range of doses studied (50, 100, and 200 mg) in youths, these AUC 0−∞ were dose adjusted to 100 mg and compared to adults using a linear mixed effect model with population (adults vs youths) as fixed effect. The least squares (LS) geometric mean ratio (GMR; youths/adults) and corresponding 90% CI for sitagliptin AUC 0−∞ were computed. Due to non-dose proportionality of sitagliptin C max and C 24hr these parameters were analyzed at 200 mg (the only dose common to the youth and adults) using the above linear fixed effect model.
Summary statistics for renal clearance and percent of sitagliptin recovered in urine over 24 hours were calculated.
| Pharmacodynamics
The 
| Power (Primary PK Hypothesis)
In designing this study, the AUC 0−∞ comparison bounds of 0.50 to 2.00-fold were used as a means to assess if the PK in youths are similar to the previously collected data in adults. This comparison bound has previously been utilized in comparing in sitagliptin PK in other populations, including those with renal impairment 25 and hepatic impairment, 26 and was used as the basis for establishing dose adjustments for people with varying degrees of renal impairment. Assuming a true GMR for AUC 0−∞ for the 10-to 17-year-old patients with respect to adults of 1.00, a sample of n 1 = 6 youths (each panel in the current study) and n 2 = 7 adults (historical data, 21 ) provide >99% probability of yielding a 90% CI for AUC 0−∞ GMR within the interval of [0.50, 2.00]. These calculations were made during the design phase of the study and were based upon between-participant standard deviation (natural log scale) for AUC 0−∞ of 0.23 ln μM•hour obtained from the reference adult study. 21 
| Data availability
Merck & Co., Inc.'s data sharing policy, including restrictions, is available at http://engagezone.merck.com/ds_documentation.php.
Requests for access to the study data can be submitted through the EngageZone site or via email to dataaccess@merck.com.
| RESULTS
The study was initiated on 25 
| Study Participants
Thirty-five 10-to 17-year-old patients with T2DM were enrolled and 34 completed the study. One participant withdrew consent and discontinued because of difficulty maintaining venous access for the protocol-specified blood samples. The mean body weight of participants 10 to 13 years of age was 92.8 kg (n = 12) and of those 14 to <18 years of age was 89.9 kg (n = 23). The demographic characteristics of each dose panel were similar, with means of the ages in the dosing panels ranging from 13.9 to 14.8 years, of fasting plasma glucose levels ranging from 97.6 to 109.7 mg/dL (5.4 to 6.1 mmol/L), and of HbA1c levels ranging from 6.0 to 6.6% (42 to 49 mmol/mol) ( Table 1) . Twenty-seven of the study participants were being treated with metformin for at least 12 weeks immediately prior to receiving study treatment. The other 8 participants were not being treated with any antihyperglycemic agent within 12 weeks of receiving study medication. (Table 2 ).
| Safety and tolerability
| Pharmacokinetics
The plasma sitagliptin time-concentration profile and the principal sitagliptin PK parameters after single oral doses of sitagliptin (50, 100, or 200 mg) administered to youths with T2DM are summarized in Figure 1 and Table 3 Information Table S1 ). No clear trend in difference from these clearance rates was observed in subgroups of participants segregated by age or by gender (Table S1 ). Over 24 hours, the fraction of administered doses recovered in the urine as parent drug ranged from approximately 53% to 57%.
Comparisons between sitagliptin AUC 0−∞ , C max , and C 24hr in youths (current study) and adults 21 with T2DM are shown in A similar analysis previously carried out in adults with T2DM yielded a nearly identical inhibition curve (overlay in Figure S1 ) and IC 50.
| Pharmacodynamics
21
Compared with placebo, the WM 2-hour OGTT and post-meal plasma glucose concentrations were reduced after all sitagliptin doses, but the reductions were not statistically significant (Table S3 ). In every sitagliptin dose group, compared with placebo a statistically significant increase in WM 2-hour post-meal active GLP-1 was observed, while the WM total GLP-1 did not change (Table S3 ). The effects of single doses of sitagliptin on post-OGTT and post-meal WM glucagon, insulin, and C-peptide are also shown in Table S3 .
The ratios of active/total GLP-1 plasma concentrations were elevated for all three doses of sitagliptin relative to placebo after both the OGTT and the standardized meal (Figure 4 ).
| DISCUSSION
This is the first study to evaluate the safety, tolerability, PK, and PD of sitagliptin in 10-to 17-year-old patients with T2DM. Single oral doses of 50, 100, and 200 mg sitagliptin were administered in the fasting state, and were absorbed with a median T max of 3 hours.
Consistent with previous observations in healthy adults, 24 sitagliptin AUC 0−∞ increased in a dose-proportional manner across the 50 to 200 mg dose range in 10-to 17-year-old patients with T2DM, and renal clearance was approximately constant across doses, suggesting overall linear clearance. Also consistent with adult subjects, sitagliptin C max increased in a greater than dose-proportional manner in the youths and C 24hr increased in a less than dose proportional manner, suggesting potential nonlinear volume of distribution. 24 Due to the dose proportionality of AUC 0−∞, data for this PK parameter from all doses of sitagliptin used in this and the previous study in adults 21 could be compared directly. In 10-to 17-year-old Values shown for AUC, C max , and C 24hr are back-transformed least squares geometric mean (95% confidence interval [CI]) from a linear fixed effect model with treatment as fixed effect performed on natural log-transformed values; for T max the value shown is median (min, max) and for apparent terminal t ½ the harmonic mean with jack-knife standard deviation is shown. a Dose proportionality is assessed using power law model in natural log scale. In the back-transformed scale, the model is A = α (dose) β where α and β are intercepts and slope, respectively, and A is PK parameter; the inclusion of 1 in the 90% CI of the slope is indicative of dose proportionality across the range of doses studied. patients with T2DM, sitagliptin had an approximately 18% lower AUC 0−∞ compared with adults with T2DM. 21 However, the 90% CI of the LS GMR (youths/adults) for AUC 0−∞ was contained within the protocol prespecified bounds (0.50, 2.00) for similarity between youths and adults, satisfying the primary PK hypothesis of the study.
The observed difference in sitagliptin AUC 0−∞ between the 10-to 17-year-old patients and adults is therefore not considered to be clinically meaningful.
Because the sitagliptin C max and C 24hr did not change in a doseproportional manner across the doses in this study, comparisons of these parameters in 10-to 17-year-old patients with those observed in adults with T2DM were limited to the 200 mg dose which was common to both studies. At this dose, plasma C max was similar in youths and adults, 21 whereas C 24hr levels were modestly (~26%) lower in youths than in adults. 21 As with the AUC 0−∞ described above, the 90% CI of the GMR (youths/adults) for these parameters were contained within the protocol prespecified bounds of (0.50, 2.00) affirming the comparability of the concentration-time profile of sitagliptin following single-dose oral administration of sitagliptin between pediatric and adult populations with T2DM. These data suggest that in pediatric patients, the use of the adult dose of 100 mg daily would be expected to result in comparable peak and overall drug concentrations in these patients compared to adults, which is an important consideration in assessing the benefit and risk in dose selection for pediatric populations.
The rate and extent of sitagliptin renal elimination was similar between 10-to 17-year-old patients with T2DM and healthy adults, 24 and there was no apparent difference in renal elimination between younger (10 to <14 year-old) and older (14-17 year-old) youths.
Therefore, as in adults with T2DM, sitagliptin dose adjustment is expected to be required for pediatric patients with T2DM with moderate or severe renal insufficiency. 
